<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Clinical and Experimental Medicine</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/76352B57-0623-44D3-B54F-9A7A3AF470B3"><gtr:id>76352B57-0623-44D3-B54F-9A7A3AF470B3</gtr:id><gtr:firstName>Wiebke</gtr:firstName><gtr:surname>Arlt</gtr:surname><gtr:orcidId>0000-0001-5106-9719</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0900567"><gtr:id>5DFA25CA-0429-4C00-93D4-DD84283C93C7</gtr:id><gtr:title>P450 oxidoreductase: Novel regulator of steroid synthesis and metabolism in health and disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900567</gtr:grantReference><gtr:abstractText>The human adrenal gland produces the hormone dehydroepiandrosterone (DHEA), which is a major precursor for the production of androgens, i.e. active male hormones, in both men and women. Too much androgen in women can cause irregular periods, infertility, acne and increases the risk to diabetes and high blood pressure, summarised by the term polycystic ovary syndrome. This condition affects 5-10% of all women. We have discovered two novel mechanisms that regulate the production and the breakdown, respectively, of DHEA. Patients who have a mutation, i.e. a small spelling error in their genetic code, affecting one of the two factors we have identified, POR and PAPSS2, suffer from androgen excess. Our research will aim to find out by what mechanisms disruption of POR and PAPSS2 causes androgen excess. POR and PAPSS2 also play an important role in regulating the metabolism of drugs and hormones in the liver and thus our research will also give important insights in these mechanisms. Clarification of these two novel regulatory pathways in human physiology and disease carries clear translational potential, i.e. comes with the possibility of applying new knowledge to the development of novel therapies.</gtr:abstractText><gtr:technicalSummary>The proposed research will investigate the role of two novel metabolic pathways in human health and disease. We recently discovered that mutations in P450 oxidoreductase (POR) and PAPS synthase 2 (PAPSS2) disrupt dehydroepiandrosterone (DHEA) synthesis and metabolism, respectively, resulting in androgen excess, a major feature of the polycystic ovary syndrome (PCOS). POR has a pivotal role as electron donor to all microsomal cytochrome P450 (CYP) enzymes including key enzymes of steroidogenesis and hepatic drug metabolism. In this proposal we will define the differential impact of variant POR on steroidogenesis and hepatic drug detoxification. POR deficiency is unique in that affected children of both sexes can present with disordered sex development. Undervirilisation in boys is readily explained by impaired DHEA synthesis, which however is incongruous with virilisation in affected girls. We have proposed that this apparent contradiction is explained by an alternative androgen pathway in early human life, with recent evidence supporting this hypothesis. We will examine the role of the alternative androgen pathway in human sex development, analysing its expression and activity during pregnancy and the early neonatal period in normal and disordered sex development. DHEA is the major precursor of androgen synthesis via the classic pathway unless inactivated to DHEAS by DHEA sulfotransferase, which requires the universal sulfate donor PAPS for catalytic activity. We have identified inactivating mutations in PAPSS2 encoding human PAPS synthase 2 in a girl presenting with premature pubarche followed by development of PCOS. We have established PAPSS2 deficiency as a novel monogenic cause of androgen excess, revealing DHEA sulfation as a gatekeeper to human androgen synthesis. We will identify and characterise further cases of PAPSS2 deficiency in premature pubarche and PCOS. Furthermore, we will examine whether common variation in PAPSS2 contributes to PCOS susceptibility by performing dense tagSNP genotyping in large PCOS and control cohorts. Finally, we will analyse the differential effects of the two PAPS synthase isoforms to clarify why ubiquitously expressed PAPSS1 cannot compensate for the loss of PAPSS2 activity. Taken together, this programme of research will investigate the physiological and clinical significance of two crucial metabolic pathways, the provision of electrons by POR to microsomal CYP enzymes and the provision of PAPS to sulfotransferases. The clinical significance of an improved understanding of these systems cannot be underestimated and includes a major modulatory role of POR and PAPS in hepatic phase 1 and phase 2 detoxification, current key targets of pharmacogenomics.</gtr:technicalSummary><gtr:fund><gtr:end>2014-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>948993</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>EuroDSD Consortium</gtr:description><gtr:id>1D7BD50D-153F-4B19-9854-245EFEEC3B15</gtr:id><gtr:impact>There is indeed an output as the EU FP7 collaborative network has been funded</gtr:impact><gtr:outcomeId>720A01FFD27-1</gtr:outcomeId><gtr:partnerContribution>increased collaboration and networking across Europe</gtr:partnerContribution><gtr:piContribution>I am the workpackage leader for steroid analysis/steroid metabolomics for this Collaborative Research Network, which is EU FP7 funded and is dedicated to the investigation of the molecular pathogenesis of disordered sex development, expertise arising from my MRC Senior Clinical Fellowship</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>305385</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome CRTF</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>WT099909MA</gtr:fundingRef><gtr:id>BA918C48-B9C0-4EB4-93C4-C0E98E2DEC71</gtr:id><gtr:outcomeId>Nkzch6yiCxG</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>FP7 DSD-Life</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>B25A4914-0E2B-4AF9-867C-1637C8819452</gtr:id><gtr:outcomeId>pB2PAjSNUK9</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1800000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Commission FP7 - Marie Curie Initial Training Network (Multi-Site ITN)</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Marie Sklodowska-Curie Actions</gtr:fundingOrg><gtr:id>8FB6CBE8-3F71-4DAE-BF5D-4529248D0BC1</gtr:id><gtr:outcomeId>svdYNXLQKyf0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>180000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Marie Curie European Fellowship</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>CB1E48D0-738E-45EF-B3A0-E9DC852E6552</gtr:id><gtr:outcomeId>54645a9f4b5738.69671855</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>140000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DTG PhD Consortium &amp;quot;Translational Steroid Endocrinology&amp;quot;</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>14437EEB-78F8-48A3-9C16-FE3B99D5C345</gtr:id><gtr:outcomeId>Cr7vT2AthLx0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Chair, UK Taskforce for Management of Adults with Congenital Adrenal Hyperplasia</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>5D362657-C864-4C0D-B9E0-BC277CDE81CD</gtr:id><gtr:outcomeId>VacZpbFaYv1</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member, UK Taskforce for Disordered Sex Development</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>7C62B70A-08A9-4AAA-8299-C6E2002DD58C</gtr:id><gtr:outcomeId>EKWyMF6Fon4</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F8965165-6A31-4CBA-981E-E62993BB69B1</gtr:id><gtr:title>Quality of life in adults with congenital adrenal hyperplasia relates to glucocorticoid treatment, adiposity and insulin resistance: United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE).</gtr:title><gtr:parentPublicationTitle>European journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4da58692a74f3d8edbc8cc0f3d1b0783"><gtr:id>4da58692a74f3d8edbc8cc0f3d1b0783</gtr:id><gtr:otherNames>Han TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0804-4643</gtr:issn><gtr:outcomeId>pm_12491_21_23520247</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70943F48-E0C4-48A7-B1CC-1D24D3692F81</gtr:id><gtr:title>SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Emergency management of acute adrenal insufficiency (adrenal crisis) in adult patients.</gtr:title><gtr:parentPublicationTitle>Endocrine connections</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebfa08c2a75ffac43dcfc6bc9fac293d"><gtr:id>ebfa08c2a75ffac43dcfc6bc9fac293d</gtr:id><gtr:otherNames>Arlt W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2049-3614</gtr:issn><gtr:outcomeId>58b927c990e7a6.69865076</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3C68F66-2F6D-4AF8-940E-E26BA1EDEEC3</gtr:id><gtr:title>The modulation of corticosteroid metabolism by hydrocortisone therapy in patients with hypopituitarism increases tissue glucocorticoid exposure.</gtr:title><gtr:parentPublicationTitle>European journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac7697bc61684200b8357127375ee26d"><gtr:id>ac7697bc61684200b8357127375ee26d</gtr:id><gtr:otherNames>Sherlock M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0804-4643</gtr:issn><gtr:outcomeId>56e11c5ea47616.61536148</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3170FD8-E5B3-43FF-BC2A-7824C64FCCBA</gtr:id><gtr:title>Novel associations in disorders of sex development: findings from the I-DSD Registry.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fedf8c58fa297cdc0f3e37be1add650c"><gtr:id>fedf8c58fa297cdc0f3e37be1add650c</gtr:id><gtr:otherNames>Cox K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>546459d87f5066.47306697</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B3BBC27-2481-4B2C-8F72-FBCBCA9F781F</gtr:id><gtr:title>Genotype-phenotype correlation in 153 adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: analysis of the United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE) cohort.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e137afff12d4533ad673529045e90711"><gtr:id>e137afff12d4533ad673529045e90711</gtr:id><gtr:otherNames>Krone N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>pm_12491_21_23337727</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25C5EFA6-3D58-460A-8ED0-3463FA943168</gtr:id><gtr:title>Salivary Cortisone Reflects Cortisol Exposure Under Physiological Conditions and After Hydrocortisone.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57c7e7933f54893a2ead60368a229e39"><gtr:id>57c7e7933f54893a2ead60368a229e39</gtr:id><gtr:otherNames>Debono M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>56e11cc8869226.12836219</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>454F139A-3991-4E7D-9F9A-1A573C71FC68</gtr:id><gtr:title>Diagnosis and management of adrenal insufficiency.</gtr:title><gtr:parentPublicationTitle>The lancet. Diabetes &amp; endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c2fa798f4e6726a0e333148051d4950"><gtr:id>4c2fa798f4e6726a0e333148051d4950</gtr:id><gtr:otherNames>Bancos I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2213-8587</gtr:issn><gtr:outcomeId>546459d7531811.43212523</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62D16CAF-0888-4690-B49D-AF28CA26BB56</gtr:id><gtr:title>Health problems in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</gtr:title><gtr:parentPublicationTitle>Hormone research in paediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/897def9e6641f128d0df385dc5f3ddd9"><gtr:id>897def9e6641f128d0df385dc5f3ddd9</gtr:id><gtr:otherNames>Reisch N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1663-2818</gtr:issn><gtr:outcomeId>g9MbAA6EoBz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3EAA389-2316-426B-ADB4-AD8D16811B0F</gtr:id><gtr:title>Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol.</gtr:title><gtr:parentPublicationTitle>European journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25f3ec830f0d034469efbb20665c8c68"><gtr:id>25f3ec830f0d034469efbb20665c8c68</gtr:id><gtr:otherNames>Woods CP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0804-4643</gtr:issn><gtr:outcomeId>56e11c5e40e0b9.15191088</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19C4AE80-F1ED-485C-A473-A904A640F54D</gtr:id><gtr:title>Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone.</gtr:title><gtr:parentPublicationTitle>Cancer treatment reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/425b768663ffc7ce9141f0a1e50bfe23"><gtr:id>425b768663ffc7ce9141f0a1e50bfe23</gtr:id><gtr:otherNames>Pia A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-7372</gtr:issn><gtr:outcomeId>pm_12491_21_23582279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0536D6F-1BCE-4725-BA41-DF083A349D95</gtr:id><gtr:title>Characterization of the molecular genetic pathology in patients with 11?-hydroxylase deficiency.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/faac6abb6c85eeae7848b053c83f70a4"><gtr:id>faac6abb6c85eeae7848b053c83f70a4</gtr:id><gtr:otherNames>Mooij CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>56e11c5ee699b5.84043774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D200D72-9C95-46C4-977D-0C7416E52C2B</gtr:id><gtr:title>Congenital adrenal hyperplasia.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03936bc8579533a5ce1f82737025978d"><gtr:id>03936bc8579533a5ce1f82737025978d</gtr:id><gtr:otherNames>El-Maouche D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5aa65bdc333d19.38130948</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BB46584-BF9E-4D19-ACF8-D09D19E3479F</gtr:id><gtr:title>Role of ALADIN in human adrenocortical cells for oxidative stress response and steroidogenesis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/302f4efd784e38c5ae1c43f87c1f2939"><gtr:id>302f4efd784e38c5ae1c43f87c1f2939</gtr:id><gtr:otherNames>J?hlen R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56e11c5f1deda3.29537029</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98654326-0B0E-455F-85F9-405C1E60F5D8</gtr:id><gtr:title>Bilateral Testicular Tumors Resulting in Recurrent Cushing Disease After Bilateral Adrenalectomy.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/684e74d4e19e7c0c07ae93b4a0bfcbdc"><gtr:id>684e74d4e19e7c0c07ae93b4a0bfcbdc</gtr:id><gtr:otherNames>Puar T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>58b927c9b59d02.65419543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53E91BB5-2354-4526-8877-A9A8C170D41D</gtr:id><gtr:title>A feminizing adrenocortical carcinoma in the context of a late onset 21-hydroxylase deficiency.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44678f6b2a65a8173dc3bd0101d2f870"><gtr:id>44678f6b2a65a8173dc3bd0101d2f870</gtr:id><gtr:otherNames>Lib? R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>pm_540e16ae16a429ae7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24EA088D-5A48-4C61-92F0-EAF3EAEC6EE4</gtr:id><gtr:title>Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency.</gtr:title><gtr:parentPublicationTitle>European journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7bcf2669f9c8e1a1c4cf1eca013ca26"><gtr:id>b7bcf2669f9c8e1a1c4cf1eca013ca26</gtr:id><gtr:otherNames>Tomalik-Scharte D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0804-4643</gtr:issn><gtr:outcomeId>MKNgU3LELry</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93A2A603-FB57-444C-A7FD-4E1121ABC215</gtr:id><gtr:title>Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c5ee83798ec61595b58e2bb52b33b97"><gtr:id>8c5ee83798ec61595b58e2bb52b33b97</gtr:id><gtr:otherNames>Attard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>pm_12491_21_22170708</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E9151B2-429F-40EE-AFFB-3921C49557D3</gtr:id><gtr:title>Influence of 17-Hydroxyprogesterone, Progesterone and Sex Steroids on Mineralocorticoid Receptor Transactivation in Congenital Adrenal Hyperplasia.</gtr:title><gtr:parentPublicationTitle>Hormone research in paediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/faac6abb6c85eeae7848b053c83f70a4"><gtr:id>faac6abb6c85eeae7848b053c83f70a4</gtr:id><gtr:otherNames>Mooij CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1663-2818</gtr:issn><gtr:outcomeId>56e11cc92feff3.71955619</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48BA8486-E4F9-4687-96B4-2DB8E1F60378</gtr:id><gtr:title>Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebfa08c2a75ffac43dcfc6bc9fac293d"><gtr:id>ebfa08c2a75ffac43dcfc6bc9fac293d</gtr:id><gtr:otherNames>Arlt W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>QbVo8tozu7i</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>991E3912-EB4D-4E02-BBAD-285394A7BA7E</gtr:id><gtr:title>46,XY disorder of sex development in a sudanese patient caused by a novel mutation in the HSD17B3 gene.</gtr:title><gtr:parentPublicationTitle>Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and pathology of sex determination and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15af903629ea840dab68d2c6537e125a"><gtr:id>15af903629ea840dab68d2c6537e125a</gtr:id><gtr:otherNames>Ellaithi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1661-5425</gtr:issn><gtr:outcomeId>546459d79ad969.56822357</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4A1AE7E-6BBD-4D18-B45A-8F346C79EDA2</gtr:id><gtr:title>Steroid Sulfatase Deficiency and Androgen Activation Before and After Puberty.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a59dd2557fd3beeb2639ff29bf8bdd2e"><gtr:id>a59dd2557fd3beeb2639ff29bf8bdd2e</gtr:id><gtr:otherNames>Idkowiak J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>58b927caa02744.36366388</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F627C382-39E7-461D-83F1-68D7043B3CB5</gtr:id><gtr:title>Impaired 17,20-Lyase Activity in Male Mice Lacking Cytochrome b5 in Leydig Cells.</gtr:title><gtr:parentPublicationTitle>Molecular endocrinology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db0fa8f4ecccc8e12ec514f73cedca53"><gtr:id>db0fa8f4ecccc8e12ec514f73cedca53</gtr:id><gtr:otherNames>Sondhi V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0888-8809</gtr:issn><gtr:outcomeId>58b927ca0fe9c7.25520311</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FABC447-32D9-41B9-B4A6-0DF95EF50909</gtr:id><gtr:title>Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1fd0e5fe1c216629fcf28b9a267c24d"><gtr:id>c1fd0e5fe1c216629fcf28b9a267c24d</gtr:id><gtr:otherNames>Bornstein SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>56e11c5dc65158.83611683</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED223134-1BB5-4C59-91C2-39614463E4EC</gtr:id><gtr:title>TAC3/TACR3 mutations reveal preferential activation of gonadotropin-releasing hormone release by neurokinin B in neonatal life followed by reversal in adulthood.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18579393d780fe6e772d51e4b5a3b245"><gtr:id>18579393d780fe6e772d51e4b5a3b245</gtr:id><gtr:otherNames>Gianetti E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>rcjUckd1zK5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2ED5734E-CDE4-4DEC-AB7D-AF3E66E0E920</gtr:id><gtr:title>How to avoid precipitating an acute adrenal crisis.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f35ac11500664ec2a8d1e06b08e2f2e"><gtr:id>8f35ac11500664ec2a8d1e06b08e2f2e</gtr:id><gtr:otherNames>Wass JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>pm_12491_21_23048013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D175F87C-D485-4794-A3A0-8EE5D3A84248</gtr:id><gtr:title>PAPSS2 deficiency causes androgen excess via impaired DHEA sulfation--in vitro and in vivo studies in a family harboring two novel PAPSS2 mutations.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83f881ad14c4d84fa5b07fde7a5d33f1"><gtr:id>83f881ad14c4d84fa5b07fde7a5d33f1</gtr:id><gtr:otherNames>Oostdijk W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>54c96f4940ac60.96227969</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1743E5F9-6BED-47BF-B2E5-4C27C2F2CF3C</gtr:id><gtr:title>Functional consequences of seven novel mutations in the CYP11B1 gene: four mutations associated with nonclassic and three mutations causing classic 11{beta}-hydroxylase deficiency.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07cb24192f79752a8bf8555f99b9be72"><gtr:id>07cb24192f79752a8bf8555f99b9be72</gtr:id><gtr:otherNames>Parajes S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>JefnEv6j7Le</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>625F69BF-87EA-4118-8099-92EFCCA39051</gtr:id><gtr:title>The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58bfd71fbbd42020ba6ceca87a1fcda7"><gtr:id>58bfd71fbbd42020ba6ceca87a1fcda7</gtr:id><gtr:otherNames>Shaw GL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>56e11c5df0b904.48234589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85222071-24A1-45F7-8091-4CD36C03D1C5</gtr:id><gtr:title>Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1634e3ed1dc63990907a8dbc9922d3e"><gtr:id>b1634e3ed1dc63990907a8dbc9922d3e</gtr:id><gtr:otherNames>Wierman ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>546459d6d42832.79634213</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32C325C0-0CE5-4AB3-AC55-61BC12A4EDA3</gtr:id><gtr:title>Concomitant mutations in the P450 oxidoreductase and androgen receptor genes presenting with 46,XY disordered sex development and androgenization at adrenarche.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a59dd2557fd3beeb2639ff29bf8bdd2e"><gtr:id>a59dd2557fd3beeb2639ff29bf8bdd2e</gtr:id><gtr:otherNames>Idkowiak J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>C14umT29jLx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B663A734-122C-451E-A89B-04D5273B1F4C</gtr:id><gtr:title>UK guidance on the initial evaluation of an infant or an adolescent with a suspected disorder of sex development.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0027443994fea85a83181a1292521a7"><gtr:id>d0027443994fea85a83181a1292521a7</gtr:id><gtr:otherNames>Ahmed SF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>TJyB4eMvEpr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>279A44A1-8E6C-460C-ADB2-0572F67A7F43</gtr:id><gtr:title>Treatment and health outcomes in adults with congenital adrenal hyperplasia.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4da58692a74f3d8edbc8cc0f3d1b0783"><gtr:id>4da58692a74f3d8edbc8cc0f3d1b0783</gtr:id><gtr:otherNames>Han TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1759-5029</gtr:issn><gtr:outcomeId>pm_540e16ae16a37406d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9218A5A2-29EC-493F-B594-B325851D99C8</gtr:id><gtr:title>Pubertal presentation in seven patients with congenital adrenal hyperplasia due to P450 oxidoreductase deficiency.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a59dd2557fd3beeb2639ff29bf8bdd2e"><gtr:id>a59dd2557fd3beeb2639ff29bf8bdd2e</gtr:id><gtr:otherNames>Idkowiak J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>C0AA40D2_9C0AA40D2_9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DE3AB7B-6147-41F1-AA3B-921C69ABBDFE</gtr:id><gtr:title>Nonclassic lipoid congenital adrenal hyperplasia masquerading as familial glucocorticoid deficiency.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/efffd827f4cf03299dd1a9576ea0f846"><gtr:id>efffd827f4cf03299dd1a9576ea0f846</gtr:id><gtr:otherNames>Metherell LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>Nb6icMH4VQh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B02AA36-2AA8-42CA-9EE2-D97DE70AA8ED</gtr:id><gtr:title>Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency.</gtr:title><gtr:parentPublicationTitle>Journal of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24a01c494c54008e764a252a1004b9a4"><gtr:id>24a01c494c54008e764a252a1004b9a4</gtr:id><gtr:otherNames>Husebye ES</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0954-6820</gtr:issn><gtr:outcomeId>546459d85bdb13.23988860</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0B2AADE-476F-4CDA-86C2-5D852088F6EC</gtr:id><gtr:title>Residual adrenal function in autoimmune Addison's disease: improvement after tetracosactide (ACTH1-24) treatment.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/035d0e4c4756ccd97aba54ac23cbeebc"><gtr:id>035d0e4c4756ccd97aba54ac23cbeebc</gtr:id><gtr:otherNames>Gan EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>pm_12491_21_24170102</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FC83B1D-D85D-4D63-860A-8C527A003361</gtr:id><gtr:title>A novel entity of clinically isolated adrenal insufficiency caused by a partially inactivating mutation of the gene encoding for P450 side chain cleavage enzyme (CYP11A1).</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07cb24192f79752a8bf8555f99b9be72"><gtr:id>07cb24192f79752a8bf8555f99b9be72</gtr:id><gtr:otherNames>Parajes S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>Lmak8dMQnRX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBEBA4BC-D3BC-47E1-9334-7C0D5D06E1C6</gtr:id><gtr:title>Glucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4da58692a74f3d8edbc8cc0f3d1b0783"><gtr:id>4da58692a74f3d8edbc8cc0f3d1b0783</gtr:id><gtr:otherNames>Han TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>pm_12491_21_22998134</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87B3CB3C-D845-4648-BC45-3A6B750A95EF</gtr:id><gtr:title>Modified-Release and Conventional Glucocorticoids and Diurnal Androgen Excretion in Congenital Adrenal Hyperplasia.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f97a453f085d472294acf37daccdeae"><gtr:id>3f97a453f085d472294acf37daccdeae</gtr:id><gtr:otherNames>Jones CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>58b927c9dddcc2.88266943</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50723A25-889B-47BE-885B-D3099448A977</gtr:id><gtr:title>Approach to the patient: the adult with congenital adrenal hyperplasia.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92526e54c1bb8b06b4e87f355fec401c"><gtr:id>92526e54c1bb8b06b4e87f355fec401c</gtr:id><gtr:otherNames>Auchus RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>pm_12491_21_23837188</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DC141BB-50E8-4A30-8271-013804249DEC</gtr:id><gtr:title>A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fdd94eaf817c63fc545999f4d783c3e"><gtr:id>2fdd94eaf817c63fc545999f4d783c3e</gtr:id><gtr:otherNames>Mallappa A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>54c96f49114124.14954151</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B07787D3-CC7C-4E5F-B6FF-8717D4DCD04A</gtr:id><gtr:title>What is the best diagnostic and therapeutic management strategy for an Addison patient during pregnancy?</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/306efc7bc96c17f6a015a9d550847bc5"><gtr:id>306efc7bc96c17f6a015a9d550847bc5</gtr:id><gtr:otherNames>Lebbe M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>pm_12491_21_23153216</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0700AC5F-AF1F-4E11-8A85-8FE7CBCB0C2D</gtr:id><gtr:title>Novel H6PDH mutations in two girls with premature adrenarche: 'apparent' and 'true' CRD can be differentiated by urinary steroid profiling.</gtr:title><gtr:parentPublicationTitle>European journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a440c1edea41fd8b10866dc9f79cdbc8"><gtr:id>a440c1edea41fd8b10866dc9f79cdbc8</gtr:id><gtr:otherNames>Lavery GG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0804-4643</gtr:issn><gtr:outcomeId>pm_12491_21_23132696</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB83311F-2728-4402-889A-2A8B0AB1ED09</gtr:id><gtr:title>Genotype-phenotype analysis in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e137afff12d4533ad673529045e90711"><gtr:id>e137afff12d4533ad673529045e90711</gtr:id><gtr:otherNames>Krone N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>pm_12491_21_22162478</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7353250C-73ED-4701-9871-A379B2373C37</gtr:id><gtr:title>Changes over time in sex assignment for disorders of sex development.</gtr:title><gtr:parentPublicationTitle>Pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3d37febcf5d942198d1040b28d78c39"><gtr:id>f3d37febcf5d942198d1040b28d78c39</gtr:id><gtr:otherNames>Kolesinska Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0031-4005</gtr:issn><gtr:outcomeId>546459d776a148.40375114</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3776B748-AE28-4F0A-AEEC-1DAF2913A65E</gtr:id><gtr:title>A diagnosis not to be missed: nonclassic steroid 11?-hydroxylase deficiency presenting with premature adrenarche and hirsutism.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/897def9e6641f128d0df385dc5f3ddd9"><gtr:id>897def9e6641f128d0df385dc5f3ddd9</gtr:id><gtr:otherNames>Reisch N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>pm_12491_21_23940125</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1E009D7-DCAB-4121-A4B8-C22ADFD5C5B2</gtr:id><gtr:title>A detour guide to the Endocrine Society Clinical Practice Guideline on case detection, diagnosis and treatment of patients with primary aldosteronism.</gtr:title><gtr:parentPublicationTitle>European journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebfa08c2a75ffac43dcfc6bc9fac293d"><gtr:id>ebfa08c2a75ffac43dcfc6bc9fac293d</gtr:id><gtr:otherNames>Arlt W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0804-4643</gtr:issn><gtr:outcomeId>pm_12491_11_19797500</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CC057B3-A0D1-4466-B94E-9899EAF33203</gtr:id><gtr:title>Relationship between final height and health outcomes in adults with congenital adrenal hyperplasia: United Kingdom congenital adrenal hyperplasia adult study executive (CaHASE).</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4da58692a74f3d8edbc8cc0f3d1b0783"><gtr:id>4da58692a74f3d8edbc8cc0f3d1b0783</gtr:id><gtr:otherNames>Han TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>546459d7bf6172.25246350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFEE2599-443B-43C2-908F-FE81CACCB487</gtr:id><gtr:title>Primary adrenal insufficiency is associated with impaired natural killer cell function: a potential link to increased mortality.</gtr:title><gtr:parentPublicationTitle>European journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c2fa798f4e6726a0e333148051d4950"><gtr:id>4c2fa798f4e6726a0e333148051d4950</gtr:id><gtr:otherNames>Bancos I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0804-4643</gtr:issn><gtr:outcomeId>58b927c9636ec1.19564952</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A352093-FCCC-4825-8404-9D648B85B5E4</gtr:id><gtr:title>Delayed diagnosis of adrenal insufficiency in a patient with severe penoscrotal hypospadias due to two novel P450 side-change cleavage enzyme (CYP11A1) mutations (p.R360W; p.R405X).</gtr:title><gtr:parentPublicationTitle>European journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07cb24192f79752a8bf8555f99b9be72"><gtr:id>07cb24192f79752a8bf8555f99b9be72</gtr:id><gtr:otherNames>Parajes S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0804-4643</gtr:issn><gtr:outcomeId>pm_12491_21_22968487</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60941A1F-6C13-4C56-AB4E-5697F3510215</gtr:id><gtr:title>Society for Endocrinology UK guidance on the initial evaluation of an infant or an adolescent with a suspected disorder of sex development (Revised 2015).</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0027443994fea85a83181a1292521a7"><gtr:id>d0027443994fea85a83181a1292521a7</gtr:id><gtr:otherNames>Ahmed SF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>56e11c5e8787c9.17931332</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E510AFA2-C6A9-4175-901D-BAD6B2CB1D05</gtr:id><gtr:title>Redefining the initiation and maintenance of zebrafish interrenal steroidogenesis by characterizing the key enzyme cyp11a2.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07cb24192f79752a8bf8555f99b9be72"><gtr:id>07cb24192f79752a8bf8555f99b9be72</gtr:id><gtr:otherNames>Parajes S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn><gtr:outcomeId>pm_12491_21_23671259</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31AFBFBF-F2AC-4BB0-AB5D-BF81D5A80B04</gtr:id><gtr:title>A missense mutation in the human cytochrome b5 gene causes 46,XY disorder of sex development due to true isolated 17,20 lyase deficiency.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a59dd2557fd3beeb2639ff29bf8bdd2e"><gtr:id>a59dd2557fd3beeb2639ff29bf8bdd2e</gtr:id><gtr:otherNames>Idkowiak J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>pm_12491_21_22170710</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8886758A-D4ED-4A33-B52B-6A63F92272F3</gtr:id><gtr:title>A rare cause of congenital adrenal hyperplasia: Antley-Bixler syndrome due to POR deficiency.</gtr:title><gtr:parentPublicationTitle>The Netherlands journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fe35d51ea5eea0e79bba16fa6a923ec"><gtr:id>9fe35d51ea5eea0e79bba16fa6a923ec</gtr:id><gtr:otherNames>Herkert JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-2977</gtr:issn><gtr:outcomeId>fivsyqEJi37</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B076CA27-59F1-46B6-B311-2A310FFC5B65</gtr:id><gtr:title>Neutrophil function in young and old caregivers.</gtr:title><gtr:parentPublicationTitle>British journal of health psychology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30c2eb965757b1a6a22070191a39cc08"><gtr:id>30c2eb965757b1a6a22070191a39cc08</gtr:id><gtr:otherNames>Vitlic A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1359-107X</gtr:issn><gtr:outcomeId>56e11c5e6312a0.44370859</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24774EBE-5E0E-4AEE-9C96-8A47530DA869</gtr:id><gtr:title>Cortisone-reductase deficiency associated with heterozygous mutations in 11beta-hydroxysteroid dehydrogenase type 1.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/387842d227c2a593541673b0e609d2d3"><gtr:id>387842d227c2a593541673b0e609d2d3</gtr:id><gtr:otherNames>Lawson AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>FhnxPQ3PC1G</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A358420-96FE-4132-B899-9E7F7CC6C46C</gtr:id><gtr:title>Single-cell RNA sequencing reveals T helper cells synthesizing steroids de novo to contribute to immune homeostasis.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbeb7f3abb900b7f62cab77f20f48bbb"><gtr:id>fbeb7f3abb900b7f62cab77f20f48bbb</gtr:id><gtr:otherNames>Mahata B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>546459d80b7770.53433733</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC2EED99-37DA-443C-9577-DC4A9820816A</gtr:id><gtr:title>An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df8fccd6cfbdb1429a3ddbac157fb39e"><gtr:id>df8fccd6cfbdb1429a3ddbac157fb39e</gtr:id><gtr:otherNames>Whitaker M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>pm_12491_21_23980724</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900567</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>FA7AA693-7EDD-4A7E-8CA3-6B5658FBF717</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Reproductive Health and Childbirth</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>